You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
四環醫藥(00460.HK):附屬擬1.18億元出售軒升製藥100%股權 優化盈利能力、解決與軒竹生物同業競爭問題
格隆匯 04-18 19:58

格隆匯4月18日丨四環醫藥(00460.HK)宣佈,於2022年4月15日,公司全資附屬海南四環醫藥有限公司作為賣方與西藏嘉豐創業投資合夥企業(有限合夥)作為買方訂立股權轉讓協議,賣方擬向買方出售目標公司北京軒升製藥有限公司的全部已發行股本,總代價為約人民幣1.18億元。所得款項淨額將用作集團的一般營運資金。

值得一提的是,公司目前正尋求分拆附屬公司軒竹生物並於上海證券交易所科創板獨立上市。軒竹生物為公司旗下的創新藥研發子公司,擁有國內一流的小分子及大分子創新藥自主研發平台,目前擁有在研創新藥產品管線覆蓋小分子、單抗、雙抗、融合蛋白、ADC等方向,聚焦於腫瘤、消化及非酒精性脂肪肝等領域。

目標公司主要產品為鹽酸羅沙替丁醋酸酯,為H2受體阻斷劑,屬消化系統藥物。根據軒竹生物上市項目專業顧問的意見,軒竹生物研發範圍涵蓋消化系統藥物,目標公司產品在產品適應症角度,與軒竹生物存在潛在同業競爭。

另外,由於受到醫藥行業政策的影響,目標公司的虧損情況可能將持續。為了優化公司的盈利能力,同時解決軒竹生物與目標公司的同業競爭問題,公司決定將目標公司按照雙方同意的代價進行出售給買方。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account